Skip to main content

#152109

T47D/S2 Cell Line

Cat. #152109

T47D/S2 Cell Line

Cat. #: 152109

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 8-10 weeks

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Cancer cell line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne Lykkesfeldt

Institute: Danish Cancer Society

Primary Citation: Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

Tool Details
Target Details
Applications
Handling
Related Tools
References
Documentation

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: T47D/S2 Cell Line
  • Cancer: Breast cancer
  • Cancers detailed: Breast carcinoma
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: T47D
  • Organism: Human
  • Gender: Female
  • Tissue: Breast
  • Donor: Female, Caucasian, 54Y
  • Disease: Cancer
  • Growth properties: Adherent
  • Model: Cancer cell line
  • Conditional: Yes
  • Description: T47D/S2 is an adherent human breast cancer cell line used as the parental control for the tamoxifen-resistant T47D/TR-1 and T47D/TR-2 cell lines. It was derived from the T47D line through adaptation to reduced serum conditions, enabling growth inhibition by tamoxifen. T47D/S2 displays a polygonal epithelial morphology and expresses both estrogen receptor alpha (ERα) and progesterone receptor (PR). This cell line serves as a valuable model for investigating the mechanisms underlying tamoxifen resistance in hormone receptor–positive breast cancer.
  • Application: Determining molecular mechanisms around tamoxifen resistance
  • Production details: Human breast cancer cell line derived from T47-D through adaptation to reduced serum conditions, glutamax and 8ug Insulin/mL.
  • Biosafety level: 1
  • Cellosaurus id: CVCL_1D45

Target Details

  • Target: Oestrogen receptor

Applications

  • Application: Determining molecular mechanisms around tamoxifen resistance
  • Application notes: T47DS2 cells express ER alpha and progesterone receptor.

Handling

  • Format: Frozen
  • Passage number: Passage 151 (AL3707, AL3708)
  • Growth medium: Phenol red free RPMI 1640 + 2% FCS + glutamax + 8ug Insulin/ml. Fetal Calf Serum (FCS) typically contains less estrogen than Fetal Bovine Serum (FBS) and is the preferred supplement for this cell line.
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage medium: 10% DMSO in FCS
  • Storage conditions: Liquid Nitrogen
  • Subculture routine: Following thawing and counting, dilute the cell suspension with sufficient medium and distribute 5 mL each into T25 flasks to achieve a seeding density of 1.8 - 2.0 x 10^4 / cm2. Place in 37°C, 5% CO₂ incubator. Change medium after 24 hours to remove residual DMSO and then every 2-3 days. Subculture routine: Split 1:7 weekly (slow growing cell line) with Trypsin-EDTA for detachment at 37 °C for 5 minutes. Please also see detailed protocol within the Product Datasheet in the Documentation section below.
  • Mycoplasma free: Yes

Related Tools

  • Related tools: T47D/TR-1 Cell Line ; T47D/TR-2 Cell Line ; Plasmax™ cell culture medium

References

  • Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
  • Larsen et al. 2015. BMC Cancer. 15(1):1-15. PMID: 25885472.
  • Thrane et al. 2014. Oncogene. 34(32):4199-4210. PMID: 25362855.
  • Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

Documentation

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.